Although gilteritinib and quizartinib are currently indicated only for R/R cases, combination therapy with standard chemotherapy for patients with newly-diagnosed (ND) FLT3-mutant AML is now being evaluated in several phase 3 clinical trials (HOVON 156 AML/AMLSG 28-18 [14], NCT03836209 [15], QuANTUM-First [16]). The gene discussed is FLT3; the disease is acute myeloid leukemia.